Despite some amazing advances medicine has made in the past 30 years, the lack of progress has been equally amazing on some fronts. Alzheimer's disease is one of those areas where we haven't seen much progress. That may be about to change though, not because of a new biotechnology, but because of a twist on a very old idea. Investors should take note.

Investopedia Markets: Explore the best one-stop source for financial news, quotes and insights.

The Barrier, in More Ways Than One
The cause of Alzheimer's isn't a misunderstood one - it's a buildup of toxic abeta 42 proteins in the brain. The challenge has been in getting drugs to the brain to do the repair work. For years, the barrier between the brain and its blood flow - simply referred to as the blood/brain barrier - hasn't allowed medicine to be delivered to brain cells. This is because drug molecules are bigger than the tiny permeable passages in that barrier.

That changed earlier this year, however, and a handful of public companies are charging ahead with the idea of this so-called "small molecule technology." (For related reading, see Investing In The Healthcare Sector.)

A Lot of Promising Candidates
With the help of Astex Pharmaceuticals (Nasdaq:ASTX), AstraZeneca (NYSE:AZN) is working on AZD-3839 - a drug that blocks the enzyme that may ultimately induce Alzheimer's. AstraZeneca owns the drug; Astex Pharmaceuticals is supplying the technology that allows AstraZeneca to develop it. It's called "Pyramid," and it's not only being used by AstraZeneca to develop this drug, but by several other companies looking to develop other small molecule therapies ... now that they can.

Pink sheet company Intellect Neurosciences (OTCBB:ILNS) has also developed a small molecule drug-development platform (molecule), which other companies are using to develop their own Alzheimer's drugs. Pfizer (NYSE:PFE), for instance, is in Phase III testing of Intellect's ANTISENILIN as a treatment for Alzheimer's.

However, Intellect Neurosciences is also developing a couple of its own Alzheimer's treatments using CONJUMAB-A. They're simply being called RV01 and RV02 for now ('Recall-Vax'). Though both are pre-clinical, the fact that they're both small molecule founded make them worth watching.

Elan Corporation (NYSE:ELN) is working on a drug along those same lines - ELND-005 - a small molecule beta-amyloid anti-aggregation therapy (against abeta 42, specifically), that is expected to act as a treatment for Alzheimer's by preventing the buildup of a toxic protein in the brain.

The common element? Big bucks are being shelled out by some big names to develop small molecules. The Elan development speaks most favorably of the premise, in that the company's Phase II results didn't meet the targeted endpoints, yet the company is moving ahead with its development anyway.

The Bottom Line
The final chapter in the Alzheimer's race is far from written. In fact, the Alzheimer's-treatment story may be back to the beginning again. The technology this time around, however, seems to hold more promise than many other Alzheimer's treatment ideas and approved drugs have of late. Indeed, some consider current therapies ineffective to the point of uselessness.

For the company, or companies, that can get their small molecule platforms to deliver drugs as hoped, a $3 billion Alzheimer's market awaits them. That number, however, assumes the current treatment market is its full size. Remember though, most of the currently- available drugs are ineffective, and therefore, unmarketable. If a truly effective treatment option became available, some experts believe that the Alzheimer's drug market could swell to as much as $20 billion. (For related reading, see Evaluating Pharmaceutical Companies.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

At the time of writing, James Brumley did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center